Search company, investor...

Aradigm Corporation

aradigm.com

Founded Year

1991

Stage

PIPE - VI | IPO

Total Raised

$11.5M

Market Cap

0.00B

About Aradigm Corporation

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine.

Headquarters Location

3929 Point Eden Way

Hayward, California, 94545,

United States

510-265-9000

Missing: Aradigm Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aradigm Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aradigm Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aradigm Corporation is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,903 items

Aradigm Corporation Patents

Aradigm Corporation has filed 34 patents.

The 3 most popular patent topics include:

  • Piperazines
  • Bacterial diseases
  • Antibiotics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/14/2019

6/8/2021

Rare diseases, Antibiotics, Piperazines, Membrane biology, Drug delivery devices

Grant

Application Date

8/14/2019

Grant Date

6/8/2021

Title

Related Topics

Rare diseases, Antibiotics, Piperazines, Membrane biology, Drug delivery devices

Status

Grant

Latest Aradigm Corporation News

Mepolizumab associated with fewer asthma exacerbations, lower costs in Medicare population

Jan 23, 2023

Disclosures: Sethi reports receiving research funding for the Jacobs School of Medicine and Biomedical Sciences from Cipla, GSK and Sanofi; having consultant and/or advisory board roles with Aradigm, AstraZeneca, Boehringer Ingelheim, Circassia, Gilead, GSK, Merck, Nabriva, Novavax, Paratek, Pulmonx, Sunovion and Theravance; having speaking roles for AstraZeneca, Boehringer Ingelheim and GSK; and receiving royalties from UpToDate and Taylor and Francis. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Mepolizumab use was associated with fewer exacerbations, reduced oral corticosteroid use and lower costs among patients with asthma on Medicaid, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. But because this population comprises individuals aged 65 years and older as well as younger individuals with long-term disabilities, these findings may not be generalizable to the full U.S. population, Sanjay Sethi, MD, professor and chief of pulmonary, critical care and sleep medicine at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, and colleagues wrote. Data were derived from Sethi S, et al. J Allergy Clin Immunol Pract. 2022;doi:10.1016/j.jaip.2022.10.021. Sanjay Sethi “Most trial and real-world data on the impact of the use of drugs such as mepolizumab (Nucala, GSK) in patients with asthma is from young individuals,” Sethi, who is also vice president of health sciences at Jacobs School of Medicine and Biomedical Sciences, told Healio. “Asthma may differ in its manifestations and response to therapies in elderly individuals, which prompted this study.” The researchers examined data from 1,278 patients (64.3% women; mean age, 67.9 years) with one or more prescription or administration claims for mepolizumab for asthma between Jan. 1 and Dec. 31, 2017, in the CMS fee-for-services Medicare datasets. The baseline period spanned the 12 months before the index date, and the follow-up period spanned the following 12 months. Compared with the baseline period, there was a 27% relative reduction in the proportion of patients who experienced an asthma exacerbation during the follow-up period, which met statistical significance (P < .0001), as well as a 36% relative reduction in the mean number of exacerbations leading to hospitalization per patient per year (P = .0164). The number of patients with an exacerbation who needed hospitalization also fell from 99 (8%) to 60 (5%) from baseline to the follow-up, for a relative reduction of 40% (P = .0014). The proportion of patients with one claim or more for all non-mepolizumab asthma treatments additionally fell. Comparing the follow-up to the baseline period, significantly fewer patients had one or more claim for: single-agent inhaled corticosteroids (62% vs. 66%; P = .03); short-acting beta 2 agonists (76% vs. 85%; P < .0001); short-acting muscarinic agonists (22% vs. 28%; P = .003); long-acting muscarinic agonists (33% vs. 41%; P < .0001); and leukotriene receptor antagonists (64% vs. 71%; P < .001). The researchers also noted a significant 16% relative reduction in the proportion of patients with any oral corticosteroid (OCS) use from the baseline to the follow-up period (P < .0001) along with a 35% relative reduction in the mean number of OCS claims (P < .001). Total costs fell from baseline to follow-up by $888 (P = .0002), as did pharmacy costs ($275; P < .0001), outpatient costs ($341; P = .0033) and other costs including skilled nursing facilities, home health agencies and hospice ($51; P = .0011). Inpatient costs fell by $219, but this did not reach statistical significance. Further, the proportion and mean number of exacerbations and exacerbations leading to hospitalizations significantly fell from baseline to follow-up specifically for the 76% of the population who were aged 65 years or older, the researchers continued. “The response rate in this elderly population to mepolizumab, measured in terms of reduction in exacerbations, hospitalizations and OCS use, were all of a magnitude larger than we had expected,” Sethi said. “Elderly patients with asthma have more fixed airway disease, comorbid COPD and other chronic conditions that could blunt the response to biologics.” Based on these real-world findings, the researchers concluded that mepolizumab treatment was likely to result in fewer exacerbations, reductions in use of OCS, and reductions in health care costs related to exacerbations. “These findings would suggest that in the appropriate patient with severe uncontrolled asthma, biologics such as mepolizumab should be considered irrespective of the patient’s age and comorbidities,” Sethi said. However, Sethi cautioned that all such database real-world studies demonstrate association, not causation. “A randomized placebo-controlled trial in an elderly severe uncontrolled asthma population that confirms and extends the findings of this study would be the next logical step,” he said. For more information:

Aradigm Corporation Frequently Asked Questions (FAQ)

  • When was Aradigm Corporation founded?

    Aradigm Corporation was founded in 1991.

  • Where is Aradigm Corporation's headquarters?

    Aradigm Corporation's headquarters is located at 3929 Point Eden Way, Hayward.

  • What is Aradigm Corporation's latest funding round?

    Aradigm Corporation's latest funding round is PIPE - VI.

  • How much did Aradigm Corporation raise?

    Aradigm Corporation raised a total of $11.5M.

  • Who are the investors of Aradigm Corporation?

    Investors of Aradigm Corporation include Castle Creek Capital, Penn Footwear, LRG Capital Group, Heights Capital Management, Ursus Capital Management and 31 more.

  • Who are Aradigm Corporation's competitors?

    Competitors of Aradigm Corporation include CeQur, INRange Systems, eNeura Therapeutics, Vapotherm, Calibra Medical, Aeris Therapeutics, Inogen, Tandem Diabetes Care, Catheter Connections, Zeno and 23 more.

Compare Aradigm Corporation to Competitors

Z
Zeopane Microneedles

Zeopane Microneedles is a Hong Kong based company that designs and markets Zeolite micro-needles and insulin delivery patches for diabetes patients.

R
Revascular Therapeutics

ReVascular Therapeutics has pioneered advances in technology for the intravascular treatment of complex lesions and total occlusions that typically cannot be treated using current catheter-based technologies and products.

AlterG Logo
AlterG

AlterG builds technology for physical rehabilitation, training and wellness with the goal of enabling people to sustain healthy and active lives through mobility. The company's products, the Anti-Gravity Treadmills and the AlterG Bionic Leg, are designed to enhance personal mobility and wellness. Its Anti-Gravity Treadmills use Differential Air Pressure (DAP) technology, originally developed at NASA, to unweight patients to as low as 20% of their body weight, enabling them to walk or run with reduced impact. The Bionic Leg, designed for patients with neurological and orthopedic gait disorders, is a robotic assistive device that is activated by patient initiated movement and provides stability and assistance for a full range of mobility training.

H
Health Care Solutions

Respiratory and infusion therapy for patients at home. Acquired by Lincare Holdings, Inc.

C
Catheter Connections

Catheter Connections develops vascular access products that can help protect patients from life-threatening infections during infusion therapy. The company's flagship product, DualCap, a sterile, single-use device containing two disinfecting caps - one for the IV catheter needleless luer access valve (also known as the needleless injection site, port or valve) and one for the male luer connector at the end of the IV tubing - is an FDA-cleared device for disinfection and protection of both the IV catheter needleless luer access valve and the male luer connector at the end of the IV tubing. DualCap helps to prevent intraluminal contamination, the most common way IV connectors contribute to infections in long-term catheter use.

Kinetic Muscles Logo
Kinetic Muscles

Kinetic Muscles Inc, KMI, engineers and manufactures products for stroke recovery. Used in physical therapy and occpational therapy clinics, KMI's products for stroke rehabilitation help improve the quality of life of stroke survivors.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.